Multiple cell and tissue atlas projects are underway around the globe. These efforts aim to produce community resources and foster an understanding of health and disease. Key needs for these atlas-building efforts include the following:
A suite of reference Standards for multiple molecular modalities that can be adopted easily by the research community to improve quality assurance/quality control and to ensure consistent, precise, and accurate measures over time
Appropriate Healthy Reference Tissue benchmarks as comparators for disease
The National Institute of Diabetes and Digestive and Kidney Diseases is planning a public workshop to discuss the challenges and best practices for obtaining and using healthy reference tissue as a benchmark for disease and for assessing the technical variability of imaging and -omic assays. This workshop also will identify state-of-the-art, fit-for-purpose standards for these assays and stimulate discussion of the next generation of standards. The workshop aims to address these issues through the lens of kidney precision medicine while surfacing lessons learned from other fields and sharing solutions that could enhance all atlas-building efforts broadly.
Carolyn Compton, M.D., Ph.D. (Arizona State University)
Petter Bjornstad, M.D. (Children’s Hospital Colorado)
Jeff Spraggins, Ph.D. (Vanderbilt University)
Christina M. Jones, Ph.D. (NIST)
Ben Neely, Ph.D. (NIST)
Tara Hiltke, Ph.D. (NIH/NCI)
Jasmin Bavarva, Ph.D. (NIH/NCI)
Tony Dickherber, Ph.D. (NIH/NCI)
Chris Ketchum, Ph.D. (NIH/NIDDK)
Danny Gossett, Ph.D. (NIH/NIDDK)
Eric Brunskill, Ph.D. (NIH/NIDDK)
Robert Star, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Key Needs of Multiple National Institutes of Health (NIH) Atlas Efforts
To develop a suite of reference standards for multiple molecular modalities that can be adopted easily by the research community to improve quality assurance/quality control (QA/QC) and ensure consistent, precise, and accurate measures over time
To develop appropriate “healthy reference tissue” benchmarks as comparators for disease
Key Question for Workshop Participants
What healthy reference tissue(s) and/or standard(s) should I use when I run an experiment in my laboratory next week?
10:10 a.m. – 10:50 a.m.
Session One: Lessons Learned from Atlas Programs
10:10 a.m. – 10:30 a.m.
“Lessons Learned from Atlas Programs”
Carolyn Compton, M.D., Ph.D., Arizona State University
10:30 a.m. – 10:50 a.m.
“Lessons Learned from HuBMAP and nPOD Programs”
Mark Atkinson, Ph.D., University of Florida
Key Questions for Speakers
What do we know now about pre-analytics, QA/QC, and the inclusion of standards?
What are the challenges and current best practices for minimizing batch effects and technical variability to understand biological variability?
How do you prepare for different end user needs?
What potential sources of variability did you worry about most?
10:55 a.m. – 12:25 p.m.
Session Two: Understanding the Dual Role of “Healthy Tissues” as Standards and “Normal” Reference Tissue
10:55 a.m. – 11:10 a.m.
Stephen Hewitt, M.D., Ph.D., Center for Cancer Research, NCI